$HOOKHOOKIPA Pharma Inc.

📅 Upcoming

🕒 Recent(90d)

News

• Lilly sets aside up to $3.25B to tackle critical unmet need targets with InnoCare
  InnoCare Pharma is the latest addition to Eli Lilly’s dealmaking spree, which includes some of the biggest acquisitions this year: up to $7 billion for Kelonia Therapeutics in April and up to $7.8…
  biospace · 10d ago
• Merck sees pivotal victory for $3B eye disease prospect
  Merck & Co.’s Brunello trial has hit its primary endpoint, shedding light on the effects of a trispecific diabetic macular edema (DME) drug candidate that the Big Pharma bought in a $3 billion take…
  fiercebiotech · 10d ago
• Boehringer Ingelheim bets up to $1B in AI-centered solid tumor collab with Envisagenics
  Envisagenics’ platform makes use of AI to screen and detect cancer-specific RNA alterations, which Boehringer Ingelheim wants to target through various precision treatment modalities, including mul…
  biospace · 12d ago
• Telix buys ITM for $1.65B in ‘supercritical’ radiopharma M&A
  Aside from its manufacturing and distribution footprint, ITM Isotope Technologies Munich will give Telix Pharmaceuticals the late-stage ITM-11, being developed for gastroenteropancreatic neuroendoc…
  biospace · 13d ago
• Roche bets up to $1B to advance next-gen bispecifics with Dualitas
  The partners will focus R&D efforts on immunological and inflammatory conditions using Dualitas’ DualScreen Bispecific Discovery Engine platform.
  biospace · 17d ago
• Opinion: 3 lessons from the tobacco settlement on how states should use money from Meta
  “Whether it’s nicotine or algorithms, the result is the same: reinforcing a behavior that is harmful to users,” writes Susan Morrisey.
  stat · 19d ago
• Pfizer punts Seagen ADC, further muddying value of the $43B buyout
  The co-development deal comes after Pfizer reported a late-stage failure for a Seagen asset and the discontinuation of another investigational therapy developed by the company as a subsidiary of th…
  biospace · 1mo ago
• GSK inks another Asia alliance, betting up to $1.3B for HUTCHMED’s cancer therapy
  For $110 million upfront, GSK will have the exclusive global right to advance HMPL-A830, which combines an EGFR-targeting antibody with a small-molecule KRAS blocker. The asset will be studied for…
  biospace · 1mo ago
• Deal-hungry Lilly strikes up to $2.9B immuno play for Merida
  With the acquisition of Merida Biosciences, Eli Lilly is gaining a precision degradation platform for therapies that selectively target and destroy pathologic antibodies for allergic and autoimmune…
  biospace · 1mo ago
• Opinion: How to disrupt the health misinformation business model
  One way to fight medical misinformation: make it easier for people to understand when they are being manipulated, write Paul Martin Jensen and Avi Tuschman.
  stat · 1mo ago